Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China

Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China

BackgroundBrain metastasis (BM) frequently occurs in HER2-positive breast cancer (BC) patients, but the risk factors of BM in this type of patients are still unknown. Our study aims to assess the risk factors of BM and prognostic analysis in HER2-positive BC patients.MethodsUnivariate analysis used...

Full description

Bibliographic Details
Main Authors:	Shuang-Long Cai, Zhi-Hong Wang, Xiao-Geng Chen, Lei Han, Guo-Xian Gong, Yan-Ping Chen, Xiu-Quan Lin, Tao Ma, Hong-Dan Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Oncology
Subjects:	brain metastasis risk factors prognostic analysis HER2 positive breast cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.905065/full

Similar Items

Erratum: Risk factors of brain metastasis and prognosis in HER2-positive breast cancer: A single-institution retrospective analysis from China
by: Frontiers Production Office
Published: (2022-09-01)

Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
by: Michelle D. Hackshaw, et al.
Published: (2021-08-01)

Modern Management and Diagnostics in HER2+ Breast Cancer with CNS Metastasis
by: Surbhi Warrior, et al.
Published: (2023-05-01)

Histologic heterogeneity predicts patient prognosis of HER2‐positive metastatic breast cancer: A retrospective study based on SEER database
by: Yajie Wang, et al.
Published: (2023-09-01)

New insights into HER2-low breast cancer brain metastasis: A retrospective analysis
by: Hangcheng Xu, et al.
Published: (2024-02-01)

The efficacy and safety of pyrotinib in treating HER2‐positive breast cancer patients with brain metastasis: A multicenter study
by: Min Gao, et al.
Published: (2022-02-01)

Prognostic analysis of the patients with HER2-positive breast cancer adjuvant treated with trastuzumab: a report of 1 246 cases
by: LI Yuefeng, HONG Jin, LI Zhian, RUAN Guodong, CHEN Weiguo
Published: (2023-09-01)

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
by: Jenny Karlsson, et al.
Published: (2023-06-01)

Actein Inhibits Tumor Growth and Metastasis in HER2-Positive Breast Tumor Bearing Mice via Suppressing AKT/mTOR and Ras/Raf/MAPK Signaling Pathways
by: Xiao-Xiao Wu, et al.
Published: (2020-05-01)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
by: Maria Vittoria Dieci, et al.
Published: (2019-11-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

HER2‐positive breast cancer brain metastasis: A new and exciting landscape
by: Alexandra S. Zimmer, et al.
Published: (2022-04-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis
by: Jiahui Nie, et al.
Published: (2024-01-01)

Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis
by: Aadya Nagpal, et al.
Published: (2019-08-01)

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer
by: Bülent Karagöz, et al.
Published: (2015-01-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)

Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner
by: Feng Yu, et al.
Published: (2023-10-01)

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
by: Ro Jungsil, et al.
Published: (2012-07-01)

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
by: Hangcheng Xu, et al.
Published: (2022-06-01)

HER2-positive breast cancer with brain metastasis: long-lasting response after lapatinib treatment
by: Alessia D'Alonzo, et al.
Published: (2018-06-01)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
by: Tomomi Sanomachi, et al.
Published: (2023-03-01)

HER-2/neu overexpression in breast cancer
by: Rana S. Aziz, et al.
Published: (2010-10-01)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
by: Liu Yang, et al.
Published: (2022-04-01)

Radiomics signatures for predicting the Ki-67 level and HER-2 status based on bone metastasis from primary breast cancer
by: Hongxiao Zhang, et al.
Published: (2024-01-01)

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
by: Chiara Tommasi, et al.
Published: (2024-03-01)

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
by: Massimo Di Maio, et al.
Published: (2023-12-01)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
by: Dongxu Ma, et al.
Published: (2023-01-01)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
by: Hong J, et al.
Published: (2019-04-01)

Efficacy of second-line treatment with capecitabine and lapatinib in HER2-positive mammary neoplasia, with encephalic metastasis, after first-line therapy with dual anti-HER2 block
by: Tea Zeppola
Published: (2018-06-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
by: Xiaoqing Cai, et al.
Published: (2022-06-01)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
by: Yiwei Tong, et al.
Published: (2020-04-01)

Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital
by: Lilian Bringolf, et al.
Published: (2016-12-01)

Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
by: Chundi Gao, et al.
Published: (2020-04-01)

HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma
by: Lingli Chen, et al.
Published: (2022-02-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer
by: Karadag I, et al.
Published: (2023-03-01)

An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer
by: Jinmei Zhou, et al.
Published: (2022-08-01)

Good control of diffuse brain metastasis with lapatinib plus capecitabine in a patient with HER2-positive breast cancer
by: Giovanni Faggioni
Published: (2018-06-01)